[go: up one dir, main page]

EP1789451A4 - TIE COMPLEX BINDING PROTEINS - Google Patents

TIE COMPLEX BINDING PROTEINS

Info

Publication number
EP1789451A4
EP1789451A4 EP05784935A EP05784935A EP1789451A4 EP 1789451 A4 EP1789451 A4 EP 1789451A4 EP 05784935 A EP05784935 A EP 05784935A EP 05784935 A EP05784935 A EP 05784935A EP 1789451 A4 EP1789451 A4 EP 1789451A4
Authority
EP
European Patent Office
Prior art keywords
binding proteins
complex binding
tie complex
tie
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05784935A
Other languages
German (de)
French (fr)
Other versions
EP1789451A2 (en
Inventor
Clive R Wood
Daniel T Dransfield
Henk Pieters
Rene Hoet
Simon E Hufton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dyax Corp
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2004/026116 external-priority patent/WO2005019267A2/en
Priority claimed from US11/049,536 external-priority patent/US7871610B2/en
Application filed by Dyax Corp filed Critical Dyax Corp
Publication of EP1789451A2 publication Critical patent/EP1789451A2/en
Publication of EP1789451A4 publication Critical patent/EP1789451A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G01N33/575—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP05784935A 2004-08-12 2005-08-09 TIE COMPLEX BINDING PROTEINS Withdrawn EP1789451A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/US2004/026116 WO2005019267A2 (en) 2003-08-12 2004-08-12 Tie1-binding ligands
US10/916,840 US7348001B2 (en) 2003-08-12 2004-08-12 Tie1-binding ligands
US11/049,536 US7871610B2 (en) 2003-08-12 2005-02-02 Antibodies to Tie1 ectodomain
PCT/US2005/028413 WO2006020706A2 (en) 2004-08-12 2005-08-09 Tie complex binding proteins

Publications (2)

Publication Number Publication Date
EP1789451A2 EP1789451A2 (en) 2007-05-30
EP1789451A4 true EP1789451A4 (en) 2009-12-02

Family

ID=35908119

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05784935A Withdrawn EP1789451A4 (en) 2004-08-12 2005-08-09 TIE COMPLEX BINDING PROTEINS

Country Status (5)

Country Link
EP (1) EP1789451A4 (en)
JP (1) JP2008532476A (en)
AU (1) AU2005272848A1 (en)
CA (1) CA2576886A1 (en)
WO (1) WO2006020706A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7871610B2 (en) 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
AR045563A1 (en) 2003-09-10 2005-11-02 Warner Lambert Co ANTIBODIES DIRECTED TO M-CSF
ES2375826T3 (en) * 2005-03-25 2012-03-06 National Research Council Of Canada METHOD FOR INSULATION OF SOLUBLE POLYPEPTIDES.
KR101273829B1 (en) 2005-05-20 2013-06-11 론자 바이올로직스 피엘씨 High-level expression of recombinant antibody in a mammalian host cell
WO2007079218A2 (en) 2005-12-30 2007-07-12 Dyax Corp. Metalloproteinase binding proteins
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
MX2008012146A (en) * 2006-03-28 2008-10-03 Biogen Idec Inc Anti-igf-ir antibodies and uses thereof.
JP2010506951A (en) * 2006-10-17 2010-03-04 ダイアックス コーポレーション Continuous combination therapy
EP2129396B1 (en) 2007-02-16 2013-08-21 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
EP2036980A1 (en) * 2007-09-14 2009-03-18 Gruber, Jens Down regulation of gene expression using virus-like particles charged with nucleic acid
BRPI0821906B1 (en) 2008-01-03 2022-06-07 The Scripps Research Institute Isolated full-length antibody, its use, polynucleotide, vector, and host cell
WO2009158432A2 (en) 2008-06-27 2009-12-30 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
EP2318548B1 (en) 2008-08-15 2013-10-16 Merrimack Pharmaceuticals, Inc. Methods and systems for predicting response of cells to a therapeutic agent
CA2748158A1 (en) * 2008-12-23 2010-07-01 Astrazeneca Ab Targeted binding agents directed to .alpha.5.beta.1 and uses thereof
KR101798679B1 (en) 2010-03-11 2017-11-16 메리맥 파마슈티컬즈, 인크. Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
CN103857699B (en) 2011-05-24 2016-08-31 泽恩格尼亚股份有限公司 Multivalent and monovalent multispecific complexes and uses thereof
US10316105B2 (en) 2011-08-19 2019-06-11 Regeneron Pharmaceuticals, Inc. Anti-TIE2 antibodies and uses thereof
EP2744827B1 (en) * 2011-08-19 2018-10-03 Regeneron Pharmaceuticals, Inc. Anti-tie2 antibodies uses thereof
BR112015023752B1 (en) 2013-03-15 2023-11-14 Zyngenia, Inc. MODULAR RECOGNITION DOMAIN (MRD), COMPLEX COMPRISING MRD AND CETUXIMAB, USES OF THE COMPLEX TO INHIBIT ANGIOGENESIS AND TREAT CANCER AND PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPLEX
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
EP3081575A1 (en) * 2015-04-12 2016-10-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti-plasmodium parasite antibodies
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
CN117083305A (en) * 2021-03-25 2023-11-17 南京金斯瑞生物科技有限公司 Antibody fusion proteins and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955291A (en) * 1992-01-09 1999-09-21 Alitalo; Kari Antibodies recognizing tie receptor tyrosine kinase and uses thereof
WO2005019267A2 (en) * 2003-08-12 2005-03-03 Dyax Corp. Tie1-binding ligands

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6365154B1 (en) * 1998-09-28 2002-04-02 Smithkline Beecham Corporation Tie2 agonist antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955291A (en) * 1992-01-09 1999-09-21 Alitalo; Kari Antibodies recognizing tie receptor tyrosine kinase and uses thereof
WO2005019267A2 (en) * 2003-08-12 2005-03-03 Dyax Corp. Tie1-binding ligands

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DRANSFIELD: "Targeting tie1 inhibits the growth of tumor xenografts as a monotherapy and has increased activity in combination with a VEGF inhibitor", EUROPEAN JOURNAL OF CANCER SUPPLEMENTS, vol. 4, no. 12, 28 September 2004 (2004-09-28), XP002550532, Retrieved from the Internet <URL:http://ex2.excerptamedica.com/ciw-04ena/index.cfm?fuseaction=CIS2002&hoofdnav=Abstracts&content=abs.details&what=AUTHOR&searchtext=huang&topicselected=*&selection=ABSTRACT&qryStartRowDetail=1> [retrieved on 20091014] *
JOSTOCK T ET AL: "Rapid generation of functional human IgG antibodies derived from Fab-on-phage display libraries", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 289, no. 1-2, 1 June 2004 (2004-06-01), pages 65 - 80, XP004520880, ISSN: 0022-1759 *
SIEMEISTER G ET AL: "TWO INDEPENDENT MECHANISMS ESSENTIAL FOR TUMOR ANGIOGENESIS: INHIBITION OF HUMAN MELANOMA XENOGRAFT GROWTH BY INTERFERING WITH EITHER THE VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR PATHWAY OR THE TIE-2 PATHWAY", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD., US, vol. 59, no. 13, 1 July 1999 (1999-07-01), pages 3185 - 3191, XP000971187, ISSN: 0008-5472 *
STEUKERS M ET AL: "Rapid kinetic-based screening of human Fab fragments", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 310, no. 1-2, 20 March 2006 (2006-03-20), pages 126 - 135, XP025158202, ISSN: 0022-1759, [retrieved on 20060320] *
TAKAGI HITOSHI ET AL: "Potential role of the angiopoietin/tie2 system in ischemia-induced retinal neovascularization.", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE JAN 2003, vol. 44, no. 1, January 2003 (2003-01-01), pages 393 - 402, XP002550533, ISSN: 0146-0404 *

Also Published As

Publication number Publication date
CA2576886A1 (en) 2006-02-23
WO2006020706A3 (en) 2006-10-12
AU2005272848A2 (en) 2006-02-23
EP1789451A2 (en) 2007-05-30
AU2005272848A1 (en) 2006-02-23
JP2008532476A (en) 2008-08-21
WO2006020706A2 (en) 2006-02-23

Similar Documents

Publication Publication Date Title
EP1789451A4 (en) TIE COMPLEX BINDING PROTEINS
CY2020009I2 (en) SCLEROSTEIN BINDING FACTORS
LT3339445T (en) INTERLEUKIN BINDING PROTEINS 13
EP1776134A4 (en) C-MET CINASE BINDING PROTEINS
NO20071302L (en) Binding domain fusion proteins
DE602007011923D1 (en) HEPATOCYTENWACHSTUMSFAKTOR- (HGF) BINDING PROTEINS
EP1474161A4 (en) TRANSGENIC BINDING PROTEINS
DK1776383T3 (en) binding Molecules
DE602004020610D1 (en) NEW PEPTIDE BINDING TO THE ERYTHROPOIETIN RECEPTOR
ATA19522003A (en) GAG BINDING PROTEINS
DK1742966T3 (en) Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
ZA200801389B (en) II-6 Binding proteins
EP1981538A4 (en) METALLOPROTEINASE BINDING PROTEINS
EP1957094A4 (en) CALCIUM BINDING PEPTIDES
DK1737971T3 (en) MIXTURES OF BINDING PROTEINS
EP1912680A4 (en) PEPTIDES HER-2
DK1809660T3 (en) THYMUS-SPECIFIC PROTEIN
PL1871804T3 (en) CCX-CKR2 binding antibodies
EP1915391A4 (en) SRA BINDING PROTEIN
DK1899308T3 (en) Triazines as protein binding ligands
FI20050547A0 (en) Binding
ES1060639Y (en) PERFECTED BINDING PROVISION
FI20041350A0 (en) Binding element
GB0423299D0 (en) Furin domain-containing proteins
FI20041026A0 (en) binding arrangement

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070308

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HOET, RENE

Inventor name: PIETERS, HENK

Inventor name: WOOD, CLIVE R.

Inventor name: HUFTON, SIMON E.

Inventor name: DRANSFIELD, DANIEL T.

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1105646

Country of ref document: HK

RIC1 Information provided on ipc code assigned before grant

Ipc: C07H 21/04 20060101ALI20091022BHEP

Ipc: C07K 16/28 20060101ALI20091022BHEP

Ipc: A61P 35/00 20060101ALI20091022BHEP

Ipc: A61K 39/395 20060101AFI20091022BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20091102

17Q First examination report despatched

Effective date: 20100303

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110510

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1105646

Country of ref document: HK